Subscribe to our Newsletters !!
Infections pose an everpresent threat to society a
Biotech Fluidics has introduced a durable dual sta
A new COVID-19 variant, BA.3.2, informally called
The sustained tensions between Iran and the United
For a number of years now, healthcare systems glob
Tofu used to be associated with Asian cuisine, but
Dear Readers, Welcome to a fresh and forward-lo
Johnson & Johnson and the US Department of Health and Human Services have expanded an agreement to support the next phase of COVID-19 vaccine candidate research and development, the company said on Saturday.
Under the agreement the company will commit approximately $604 million and the HHS Department’s Biomedical Advanced Research and Development Authority will commit approximately $454 million to support the Stage 3 ENSEMBLE trial assessing Janssen’s investigational COVID-19 vaccine candidate as a single dose in up to 60,000 volunteers worldwide, the company said in a statement.
